Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion type Assertion NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_head.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion description "[In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_provenance.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion evidence source_evidence_literature NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_provenance.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion SIO_000772 23108404 NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_provenance.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion wasDerivedFrom befree-20140225 NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_provenance.
- NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_assertion wasGeneratedBy ECO_0000203 NP155802.RAlJD2BkvtBPpeT3b3hvLZT8aY3V8RtYodFU2pkhhnHZo130_provenance.